{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:46Z","timestamp":1792218646427,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11899-023-00714-7","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T06:02:07Z","timestamp":1701928927000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Blinatumomab in Practice"],"prefix":"10.1007","volume":"19","author":[{"given":"Jeffrey","family":"Lantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"issue":"3","key":"714_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","volume":"12","author":"LM Man","year":"2017","unstructured":"Man LM, Morris AL, Keng M. New therapeutic strategies in acute lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(3):197\u2013206. https:\/\/doi.org\/10.1007\/s11899-017-0380-3.","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"714_CR2","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.24862","volume":"116","author":"S Faderl","year":"2010","unstructured":"Faderl S, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165\u201376. https:\/\/doi.org\/10.1002\/cncr.24862.","journal-title":"Cancer"},{"issue":"6","key":"714_CR3","doi-asserted-by":"publisher","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","volume":"10","author":"JAB Bispo","year":"2020","unstructured":"Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med. 2020;10(6):a034819. https:\/\/doi.org\/10.1101\/cshperspect.a034819.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"714_CR4","unstructured":"Worden FP, Khoriaty RN, Cooney KA, Deininger M. Hematology board review: blueprint study guide and Q & A. Demos Medical Publishing\/Springer Publishing Company, 2018."},{"issue":"1","key":"714_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70. https:\/\/doi.org\/10.1186\/s13045-020-00905-2.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"714_CR6","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106(12):3760\u20137. https:\/\/doi.org\/10.1182\/blood-2005-04-1623.","journal-title":"Blood"},{"issue":"25","key":"714_CR7","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114(25):5136\u201345. https:\/\/doi.org\/10.1182\/blood-2009-08-231217.","journal-title":"Blood"},{"key":"714_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/EDBK_280175","volume":"40","author":"DJ DeAngelo","year":"2020","unstructured":"DeAngelo DJ, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330\u201342. https:\/\/doi.org\/10.1200\/EDBK_280175.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"714_CR9","first-page":"1556","volume":"92","author":"RA Larson","year":"1998","unstructured":"Larson RA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556\u201364.","journal-title":"Blood"},{"issue":"12","key":"714_CR10","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788\u2013801. https:\/\/doi.org\/10.1002\/cncr.20668.","journal-title":"Cancer"},{"issue":"6","key":"714_CR11","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577\u2013e577. https:\/\/doi.org\/10.1038\/bcj.2017.53.","journal-title":"Blood Cancer J"},{"issue":"15","key":"714_CR12","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"J-M Ribera","year":"2014","unstructured":"Ribera J-M, et al. Treatment of high-risk philadelphia chromosome\u2013negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. JCO. 2014;32(15):1595\u2013604. https:\/\/doi.org\/10.1200\/JCO.2013.52.2425.","journal-title":"JCO"},{"issue":"9","key":"714_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"\u2022\u2022 Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783. Multi-institutional phase III trial which demonstrated that blinatumomab resulted in longer overall survival than chemotherapy among adult patients with relapsed or refractory B-ALL.","journal-title":"N Engl J Med"},{"issue":"9","key":"714_CR14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","volume":"60","author":"H Dombret","year":"2019","unstructured":"Dombret H, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(9):2214\u201322. https:\/\/doi.org\/10.1080\/10428194.2019.1576872.","journal-title":"Leuk Lymphoma"},{"issue":"Supplement_1","key":"714_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2019-125136","volume":"134","author":"NJ Short","year":"2019","unstructured":"Short NJ, et al. Updated results of a phase II study of reduced-intensity chemotherapy with mini-hyper-CVD in combination with inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):823\u2013823. https:\/\/doi.org\/10.1182\/blood-2019-125136.","journal-title":"Blood"},{"issue":"Supplement 1","key":"714_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2018-99-111992","volume":"132","author":"AS Advani","year":"2018","unstructured":"Advani AS, et al. Results of SWOG 1318: a phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):33\u201333. https:\/\/doi.org\/10.1182\/blood-2018-99-111992.","journal-title":"Blood"},{"issue":"Supplement_1","key":"714_CR17","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/blood-2019-129657","volume":"134","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, et al. Updated results from the phase II study of hyper-CVAD in sequential combination with blinatumomab in newly diagnosed adults with B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2019;134(Supplement_1):3807\u20133807. https:\/\/doi.org\/10.1182\/blood-2019-129657.","journal-title":"Blood"},{"issue":"14","key":"714_CR18","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"\u2022 Advani AS, et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574\u201382. https:\/\/doi.org\/10.1200\/JCO.21.01766. Phase II trial that evaluated frontline use of blinatumomab followed by POMP maintenance in patients with Ph\u2212 B-ALL (ORR 66%, 1-year OS 56%, 3-year OS 37%).","journal-title":"J Clin Oncol"},{"issue":"12","key":"714_CR19","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878\u201385. https:\/\/doi.org\/10.1016\/S2352-3026(22)00285-X.","journal-title":"Lancet Haematol"},{"issue":"17","key":"714_CR20","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"\u2022 Fo\u00e0 R, et al. Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2016272. Phase II trial that evaluated a chemotherapy-free combination of dasatinib and blinatumomab, which noted complete remission in 98% of patients and 18-month follow up OS of 95%.","journal-title":"N Engl J Med"},{"issue":"1","key":"714_CR21","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"\u2022 Jabbour E, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334. https:\/\/doi.org\/10.1016\/S2352-3026(22)00319-2. Phase II trial that evaluated a chemotherapy-free combination of ponatinib and blinatumomab, which resulted in a complete molecular response rate of 87% and a 1-year OS of 95% for patients with newly diagnosed Ph-positive ALL as well as a complete molecular response rate of 79% and a 1-year OS of 79% for patients with relapsed or refractory Ph-positive ALL.","journal-title":"Lancet Haematol"},{"key":"714_CR22","unstructured":"\u201cBLINCYTO (blinatumomab) [package insert].\u201d Thousand Oaks, CA: Amgen Inc, 2018. Accessed: Feb. 21, 2023. [Online]. Available: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf."},{"issue":"9","key":"714_CR23","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","volume":"317","author":"D Nagorsen","year":"2011","unstructured":"Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255\u201360. https:\/\/doi.org\/10.1016\/j.yexcr.2011.03.010.","journal-title":"Exp Cell Res"},{"key":"714_CR24","unstructured":"\u201cBlincyto: drug approval package.\u201d United States Food and Drug Administration, 2015. Accessed: Feb. 21, 2023. [Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/125557Orig1s007.pdf."},{"issue":"1","key":"714_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4. https:\/\/doi.org\/10.1186\/s40364-018-0116-0.","journal-title":"Biomark Res"},{"issue":"13","key":"714_CR26","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","volume":"2","author":"AS Stein","year":"2018","unstructured":"Stein AS, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2(13):1522\u201331. https:\/\/doi.org\/10.1182\/bloodadvances.2018019034.","journal-title":"Blood Adv"},{"issue":"26","key":"714_CR27","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226\u201333. https:\/\/doi.org\/10.1182\/blood-2012-01-400515.","journal-title":"Blood"},{"issue":"1","key":"714_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(14)71170-2.","journal-title":"Lancet Oncol"},{"issue":"16","key":"714_CR29","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. JCO. 2017;35(16):1795\u2013802. https:\/\/doi.org\/10.1200\/JCO.2016.69.3531.","journal-title":"JCO"},{"issue":"1","key":"714_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","volume":"2016","author":"NV Frey","year":"2016","unstructured":"Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):567\u201372. https:\/\/doi.org\/10.1182\/asheducation-2016.1.567.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"26","key":"714_CR31","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154\u20137. https:\/\/doi.org\/10.1182\/blood-2013-02-485623.","journal-title":"Blood"},{"issue":"3","key":"714_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/2040620716640422","volume":"7","author":"JE Benjamin","year":"2016","unstructured":"Benjamin JE, Stein AS. The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3):142\u201356. https:\/\/doi.org\/10.1177\/2040620716640422.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"714_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.07.013.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"714_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/14712598.2015.1041912","volume":"15","author":"B Rogala","year":"2015","unstructured":"Rogala B, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther. 2015;15(6):895\u2013908. https:\/\/doi.org\/10.1517\/14712598.2015.1041912.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"714_CR35","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1038\/bcj.2014.64","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4(9):e244\u2013e244. https:\/\/doi.org\/10.1038\/bcj.2014.64.","journal-title":"Blood Cancer J"},{"issue":"2","key":"714_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5045\/br.2022.2021163","volume":"57","author":"S Wo","year":"2022","unstructured":"Wo S, et al. Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Res. 2022;57(2):135\u201343. https:\/\/doi.org\/10.5045\/br.2022.2021163.","journal-title":"Blood Res"},{"issue":"18","key":"714_CR37","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, et al. Targeted therapy with the T-cell\u2013engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. JCO. 2011;29(18):2493\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.32.7270.","journal-title":"JCO"},{"issue":"7","key":"714_CR38","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1080\/10428194.2017.1397667","volume":"59","author":"P Vakharia","year":"2018","unstructured":"Vakharia P, Nardone B, Budris W, Hoshizaki K, Frankfurt O, West DP. Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data. Leuk Lymphoma. 2018;59(7):1759\u201361. https:\/\/doi.org\/10.1080\/10428194.2017.1397667.","journal-title":"Leuk Lymphoma"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00714-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T18:12:11Z","timestamp":1706551931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00714-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00714-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"2 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the family name of Firas El Chaer.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"El Chaer has consulted for Amgen and received clinical trial grant support (sub-investigator) to the University of Virginia from Amgen. Keng received clinical trial grant support (principal investigator) to the University of Virginia from Amgen. Reed received clinical trial grant support (sub-investigator) to the University of Virginia from Amgen. Jeffrey Lantz, Natalie Pham, and Caroline Jones declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}